NICE has called for EMDA® to be used in research programmes as a treatment for bladder cancer.
Following an interventional procedure overview of the EMDA® (Electromotive Drug Administration) treatment in June 2018, NICE issued updated guidance for clinicians in England and Wales on 30 January 2019.
The guidance recommends that EMDA® should be used as part of research studies treating Non-Muscular Invasive Bladder Cancer. There are currently studies underway at several Urology clinics including Guy’s & St Thomas’ NHS Foundation Trust in London and Salisbury District Hospital. Contact us to find a clinic near you.
In addition, NICE has recommended the use of EMDA® in the event that supplies of BCG become limited or if patients fail to tolerate BCG (occurs in approximately 30% of cases).
If you would like to introduce EMDA® to your clinic, please email email@example.com for more information.